脊髓损伤药物临床试验现状

Spinal cord injury will result in clinical patients with motor and sensory dysfunction, and produces a variety of complications. Spinal cord injury can cause patients with corresponding motor, sensory and sphincter dysfunction, and even the emergence of various complications. While the number of candidate drugs with spinal cord protection, but ultimately as a drug to market is minimal. The vast majority of drugs for spinal cord injury remain in the preclinical research stage. This paper systematically introduces neuroprotective drugs,such as corticosteroid drugs, gangliosides, monoaminergic drugs, neurotrophic factors, antioxidant and free radical scavenger, ion channel blocker, opioid receptor antagonist and Rho kinase inhibitor which have entered the stage of clinical trials for spinal cord injury, aiming to provide a strong reference for the further research and development of new drugs.